The present studies were designed to investigate the biology of GZ17-6.02 in prostate cancer cells, and to define its interaction with the FDA-approved Poly ADP-ribosyl Polymerase 1 (PARP1) therapeutic olaparib. This evidence concerns the gene PARP1 and prostate carcinoma.